Key Highlights
- Sun Pharmaceutical Industries finalized an all-cash acquisition of Organon & Co valued at $11.75 billion, debt included.
- The purchase price stands at $14.00 per share in cash for Organon shareholders.
- Organon shares jumped approximately 31% Friday following initial reports, then added another ~15% during Monday’s premarket session.
- The newly formed entity will secure a position among the world’s top 25 pharmaceutical companies, boasting pro forma revenue of $12.4 billion.
- Completion of the transaction is anticipated in early 2027, contingent upon regulatory clearances and shareholder consent.
India’s leading pharmaceutical manufacturer, Sun Pharma, revealed on Sunday its plan to acquire New Jersey-headquartered Organon & Co through a wholly cash-based transaction valued at $11.75 billion, debt included. Shareholders will receive $14.00 per share.
Organon shares experienced a substantial 31% surge on Friday when the Economic Times initially disclosed that Sun Pharma was negotiating a potential $13 billion acquisition. Following Sunday’s official announcement, the stock climbed an additional ~15% during early Monday premarket hours.
Across both trading periods, the stock registered a combined increase of approximately 46% from its pre-announcement trading level.
Organon emerged as an independent entity through a Merck spin-off in 2021, concentrating on women’s health products, biosimilars, and established branded pharmaceuticals. The company delivered revenue of $6.2 billion alongside adjusted EBITDA of $1.9 billion throughout 2025.
Sun Pharma outlined its financing strategy, combining available cash reserves with secured bank financing commitments. The transaction has received unanimous approval from both companies’ boards of directors.
Strategic Assets Acquired
The transaction provides Sun Pharma with a portfolio exceeding 70 products distributed throughout more than 140 nations. The acquisition positions the Indian pharmaceutical giant within the biosimilars sector, where the merged organization will rank as the seventh-largest competitor worldwide.
Organon maintains strong market positions across the United States, Europe, China, Canada, and Brazil. The company controls six production facilities distributed between the European Union and developing markets.
Macquarie analyst Dr. Kunal characterized the acquisition as “strategically and financially compelling” for Sun. He emphasized that the merged organization will derive 27% of revenue from innovative medicines, compared to Sun Pharma’s current 20%.
Sun Pharma maintains established positions in dermatology, ophthalmology, and onco-dermatology within the innovative medicines segment. Incorporating Organon’s women’s health assets would significantly broaden that therapeutic reach.
The combined organization will achieve a top-three ranking in the global women’s health pharmaceutical market.
Financial Obligations Under Review
Organon entered negotiations carrying $8.6 billion in outstanding debt alongside cash reserves of $574 million as of December 2025. The company’s net debt to EBITDA multiple measured 4 times prior to the deal announcement.
Sun Pharma maintained a net positive financial position before pursuing this acquisition. Post-transaction projections indicate the combined organization will maintain a net debt to EBITDA ratio of 2.3 times.
Bhavesh Shah of Equirus Capital observed that such transactions can deliver “value accretive results over the medium to long term,” while acknowledging near-term considerations including integration expenses and operational execution obstacles.
This marks the sixth acquisition Sun Pharma has completed over the past 16 years. Previous transactions include a 2007 acquisition of struggling Israeli pharmaceutical company Taro Pharma and the 2014 purchase of Ranbaxy Laboratories for approximately $3.2 billion.
The Organon acquisition will elevate Sun Pharma into the top 25 worldwide pharmaceutical companies, generating combined pro forma revenue totaling $12.4 billion.
The deal completion timeline targets early 2027, contingent upon receiving necessary regulatory approvals and shareholder authorization.
